Related Experiment Video
Updated: Dec 27, 2025

Author Spotlight: Exploring Salidroside's Molecular Mechanisms in Breast Cancer Treatment
Published on: June 9, 2023
Protocatechuic Aldehyde Represses Proliferation and Migration of Breast Cancer Cells through Targeting C-terminal
Yu Deng1,2, Wanjun Guo3, Guancheng Li4
1School of Medicine, Chengdu University, Chengdu, China.
Purpose:
C-terminal binding protein 1 (CtBP1) is a transcriptional co-repressor that is overexpressed in many cancers. CtBP1 transcriptionally represses a broad array of tumor suppressors, which promotes cancer cell proliferation, migration, invasion, and resistance to apoptosis. Recent studies have demonstrated that CtBP1 is a potential target for cancer therapy. This study was designed to screen for compounds that potentially target CtBP1.
Methods:
Using a structure-based virtual screening for CtBP1 inhibitors, we found protocatechuic aldehyde (PA), a natural compound found in the root of a traditional Chinese herb, Salvia miltiorrhiza, that directly binds to CtBP1. Microscale thermophoresis assay was performed to determine whether PA and CtBP1 directly bind to each other. Further, clustered regularly interspaced short palindromic repeats associated Cas9 nuclease-mediated CtBP1 knockout in breast cancer cells was used to validate the CtBP1 targeting specificity of PA.
Results:
Functional studies showed that PA repressed the proliferation and migration of breast cancer cells. Furthermore, PA elevated the expression of the downstream targets of CtBP1, p21 and E-cadherin, and decreased CtBP1 binding affinity for the promoter regions of p21 and E-cadherin in breast cancer cells. However, PA did not affect the expression of p21 and E-cadherin in the CtBP1 knockout breast cancer cells. In addition, the CtBP1 knockout breast cancer cells showed resistance to PA-induced repression of proliferation and migration.
Conclusion:
Our findings demonstrated that PA directly bound to CtBP1 and inhibited the growth and migration of breast cancer cells through CtBP1 inhibition. Structural modifications of PA are further required to enhance its binding affinity and selectivity for CtBP1.
Insights
Protocatechuic aldehyde (PA) inhibits breast cancer growth by directly binding to CtBP1, a key cancer-promoting protein. This natural compound offers a potential new avenue for cancer therapy development.
Area of Science:
- Oncology
- Molecular Biology
- Pharmacology
Background:
- C-terminal binding protein 1 (CtBP1) is an overexpressed transcriptional co-repressor implicated in promoting cancer progression.
- CtBP1's role in repressing tumor suppressors makes it a promising therapeutic target for various cancers.
- Identifying novel inhibitors of CtBP1 is crucial for developing effective cancer treatments.
Purpose of the Study:
- To screen for compounds that can inhibit the function of C-terminal binding protein 1 (CtBP1).
- To identify natural compounds with potential as CtBP1-targeted cancer therapeutics.
Main Methods:
- Structure-based virtual screening was employed to identify potential CtBP1 inhibitors.
- Protocatechuic aldehyde (PA), a natural compound, was identified and its direct binding to CtBP1 confirmed using microscale thermophoresis.
- CRISPR-Cas9 mediated CtBP1 knockout in breast cancer cells was utilized to validate PA's specificity.
Main Results:
- Protocatechuic aldehyde (PA) directly binds to CtBP1, inhibiting breast cancer cell proliferation and migration.
- PA treatment led to increased expression of CtBP1 targets (p21, E-cadherin) and reduced CtBP1 binding to their promoter regions.
- CtBP1 knockout cells demonstrated resistance to PA's anti-proliferative and anti-migratory effects, confirming PA's mechanism of action.
Conclusions:
- Protocatechuic aldehyde (PA) is a direct CtBP1 inhibitor with demonstrated efficacy in reducing breast cancer cell growth and migration.
- PA represents a potential lead compound for developing novel CtBP1-targeted cancer therapies.
- Further structural modifications of PA are necessary to optimize its binding affinity and selectivity for CtBP1.
More Related Videos
11:06Utilization of the Soft Agar Colony Formation Assay to Identify Inhibitors of Tumorigenicity in Breast Cancer Cells
Published on: May 20, 2015
13:38Synthesis and Characterization of an Aspirin-fumarate Prodrug that Inhibits NFκB Activity and Breast Cancer Stem Cells
Published on: January 18, 2017
Related Concept Videos
Inhibition of Cdk Activity
Targeted Cancer Therapies
There are several types of targeted therapies against...
Mitogens and the Cell Cycle
Abnormal Proliferation